adverse effects of glp-1 receptor agonists Unraveling the safety profile agonists: Mechanistic insights with a focus on semaglutide Glucagon-Like Peptide-1 Receptor Agonists in

1 Introduction 1.1 Literature review methodology This review was conducted by searching PubMed, Scopus, and Google Scholar databases using the keywords Parkinsons disease, -synuclein, dopaminergic neurons, LRRK2, mitochondrial dysfunction, comorbidities, levodopa, and neuroinflammation. Studies published in English between 2000 and 2025 were included

doi: 10.1002/bdrc.20101 65 ReiterRJTanDXKorkmazARosales-CorralSA

There are few or no seeds

Led by the results of cotadutide, GLP-1/glucagon co-agonists have been shown to have promising weight loss and glycaemic effects in these early phase clinical results however data from later phase clinical trials are expected later this year/early next year